Rationale and design of a randomized controlled trial of directly observed hepatitis C treatment delivered in methadone clinics

BMC Infectious Diseases

Volumn 11, Issue , 2011, Pages

  Litwin, Alain H ^a   Berg, Karina M ^a   Li, Xuan ^a   Hidalgo, Jennifer ^a   Arnsten, Julia H ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

METHADONE; PEGINTERFERON ALPHA2A; RIBAVIRIN; ALPHA INTERFERON; ANTIVIRUS AGENT; MACROGOL DERIVATIVE; RECOMBINANT PROTEIN;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIRECTLY OBSERVED THERAPY; DRUG EFFICACY; DRUG RESPONSE; DRUG SELF ADMINISTRATION; EVENING DOSAGE; FEMALE; GENOTYPE; HEPATITIS C; HISPANIC; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; METHADONE TREATMENT; MORNING DOSAGE; MULTICENTER STUDY; MULTICENTER STUDY (TOPIC); OPIATE ADDICTION; PATIENT COMPLIANCE; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SELF REPORT; SUBSTANCE ABUSE; ADDICTION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG COMBINATION; METHODOLOGY; MIDDLE AGED; OPIATE SUBSTITUTION TREATMENT; STATISTICS; TREATMENT OUTCOME;

ADULT; ANTIVIRAL AGENTS; DIRECTLY OBSERVED THERAPY; DRUG THERAPY, COMBINATION; FEMALE; HEPATITIS C; HUMANS; INTERFERON-ALPHA; MALE; MEDICATION ADHERENCE; METHADONE; MIDDLE AGED; OPIATE SUBSTITUTION TREATMENT; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; RESEARCH DESIGN; RIBAVIRIN; SUBSTANCE-RELATED DISORDERS; TREATMENT OUTCOME;

EID: 81055124139     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-11-315     Document Type: Article

References (52)

1. Hellard M, Sacks-Davis R, Gold J. Hepatitis c treatment for injection drug users: a review of the available evidence: CID. 2009, 49:561-573.
2. Sylvestre D, Clements B. Adherence to hepatitis C treatment in recovering heroin users maintained on methadone. Eur J Gastroenterol Hepatol 2007, 19:741-47. 10.1097/MEG.0b013e3281bcb8d8, 17700258.
3. Grebely J, Raffa JD, Meagher C, et al. Directly observed therapy for the treatment of hepatitis C virus infection in current and former injection drug users. Journal of Gastroenterology and Hepatology 2007, 22:1519-1525. 10.1111/j.1440-1746.2007.05032.x, 17645460.
4. McHutchison JG, Manns M, Patel K, et al. Adherence to combination therapy enhances sustained response in genotype 1-infected patients with chronic hepatitis C. Gastroenterology 2002, 123(4):1061-1069. 10.1053/gast.2002.35950, 12360468.
5. Berg KM, Litwin AH, Li X, Heo M, Arnsten JH. Directly observed antiretroviral therapy improves adherence and viral load in drug users attending methadone maintenance clinics: a randomized controlled trial. Drug and Alcohol Dependence 2010,
6. Gourevitch MN, Wasserman W, Panero MS, et al. Successful adherence to observed prophylaxis and treatment of tuberculosis among drug users in a methadone program. Journal of Addictive Diseases 1996, 15:93.
7. Shiffman ML, Di Bisceglie AM, Lindsay KL, et al. Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment. Gastroenterology 2004, 126:1015-1023. 10.1053/j.gastro.2004.01.014, 15057741.
8. Davis GL, Wong JB, McHutchison JG, et al. Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepatology 2003, 38(3):645-652. 10.1053/jhep.2003.50364, 12939591.
9. Ramos B, Nunez M, Rendon A, et al. Critical role of ribavirin for the achievement of early virological response to HCV therapy in HCV/HIV-coinfected patients. Journal of Viral Hepatitis 2007, 14:387-391. 10.1111/j.1365-2893.2006.00806.x, 17501758.
10. Bonkovsky H, Tice A, Yapp R, et al. Efficacy and safety of peginterferon alfa-2a/ribavirin in methadone maintenance patients: randomized comparison of direct observed therapy and self-administration. Am J Gastroenterol 2008, 103:2757-2765. 10.1111/j.1572-0241.2008.02065.x, 18684176.
11. Waizmann M, Ackermann G. High rates of sustained virological response in hepatitis C virus-infected injection drug users receiving directly observed therapy with peginterferon alpha-2a (40KD) (PEGASYS) and once-daily ribavirin. J Substance Abuse Treatment 2010, 38:338-345.
12. Litwin AH, Soloway I, Gourevitch MN. Integrating services for injection drug users infected with hepatitis C virus with methadone maintenance treatment: challenges and opportunities. Clinical Infectious Disease 2005, 40:S339-S345.
13. Litwin AH, Harris KA, Nahvi S, et al. Successful treatment of chronic hepatitis C with pegylated interferon in combination with ribavirin in a methadone maintenance treatment program. Journal of Substance Abuse Treatment 2009, 37:32-40. 10.1016/j.jsat.2008.09.009, 2692471, 19038524.
14. Harris KA, Arnsten JH, Litwin AH. Successful integration of hepatitis C evaluation and treatment services with methadone maintenance. J Addict Med 2010, 4(1):20-26. 10.1097/ADM.0b013e3181add3de, 2872238, 20485532.
15. Ghany M, Strader D, Thomas D, Seeff L. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009, 49:1335-1374. 10.1002/hep.22759, 19330875.
16. Renault PF, Hoofnagle JH, Park Y, Mullen KD, Peters M, Jones DB, Rustgi V, Jones EA. Psychiatric complications of long-term interferon alfa therapy. Arch Intern Med 1987, 147(9):1577-1580. 10.1001/archinte.147.9.1577, 3307672.
17. Renault PF, Hoofnagle JH. Side effects of alpha interferon. Semin Liver Dis 1989, 9(4):273-277. 10.1055/s-2008-1040523, 2690351.
18. Fontana RJ, Schwartz SM, Gebremariam A, Lok AS, Moyer CA. Emotional distress during interferon-alpha-2B and ribavirin treatment of chronic hepatitis C. Psychosomatics 2002, 43(5):378-385. 10.1176/appi.psy.43.5.378, 12297606.
19. Gavazzi SM, Julian TW, McKenry PC. Utilization of the Brief Symptom inventory to discriminate between violent and nonviolent male relationship partners. Psychol Rep 1996, 79(3 Pt 1):1047-1056.
20. Dieperink E, Ho SB, Thuras P, Willenbring ML. A prospective study of neuropsychiatric symptoms associated with interferon alpha-2b and ribavirin therapy for patients with chronic hepatitis C. Psychosomatics 2003, 44:104-112. 10.1176/appi.psy.44.2.104, 12618532.
21. Spitzer RL, Kroenke K, Williams JB. Validation and utility of a self-report version of PRIME-MD: the PHQ primary care study. Primary Care Evaluation of Mental Disorders. Patient Health Questionnaire. JAMA 1999, 282(18):1737-1744.
22. Berg KM, Mouriz J, Li X, Duggan E, Goldberg U, Arnsten JH. Rationale, design, and sample characteristics of a randomized controlled trial of directly observed antiretroviral therapy delivered in methadone clinics. Contemporary clinical trials 2009, 30:481-489. 10.1016/j.cct.2009.05.003, 2728150, 19505589.
23. Sylvestre DL, Litwin AH, Clements BJ, Gourevitch MN. The impact of barriers to hepatitis C virus treatment in recovering heroin users maintained on methadone. Journal of Substance Abuse Treatment 2005, 29(3):159-165. 10.1016/j.jsat.2005.06.002, 16183464.
24. Weiss JJ, Stivala A, Swan T, Fishbein D. Review article: adherence to medication for chronic hepatitis C - building on the model of human immunodeficiency virus antiretroviral adherence research. Alimentary Pharmacology and Therapeutics 2009, 39:14-27.
25. Smith SR, Wahed AS, Kelley SS, et al. Assessing the validity of self-reported medication adherence in hepatitis C treatment. The Annals of Pharmacotherapy 2007, 41(7):1116-1123. 10.1345/aph.1K024, 17519299.
26. Simoni JM, Kurth AE, Pearson CR, et al. Self-report measures of antiretroviral therapy adherence: a review with recommendations for HIV research and clinical management: AIDS Behav. 2006, 10(3):227-245.
27. Rodriguez-Torres M, Jeffers LJ, Sheikh MY, et al. Peginterferon alfa-2a and ribavirin in Latino and non-Latino Whites with hepatitis C. N Engl J Med 2009, 360:257-267. 10.1056/NEJMoa0805062, 19144941.
28. Muir AJ, Bornstein JD, Killenberg PG. Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-hispanic whites. N Engl J Med 2003, 350:2265-2271.
29. Jeffers L, Cassidy W, Howell CD, et al. Peginterferon alfa-2a (40 kd) and ribavirin for black American patients with chronic HCV genotype 1. Hepatology 2004, 39:1702-1708. 10.1002/hep.20212, 15185312.
30. Lucas GM, Mullen BA, McCaul ME, et al. Adherence, drug use, and treatment failure in a methadone-clinic-based program of directly administered antiretroviral therapy. AIDS Patient Care STDS 2007, 21(8):564-574. 10.1089/apc.2006.0192, 17711381.
31. Jacobson IM, McHutchison JG, Dusheiko G, et al. Telaprevir for previously untreated chronic hepatitis C infection. N Engl J Med 2011, 364(25):2405-2416. 10.1056/NEJMoa1012912, 21696307.
32. Poordad F, McCone J, Bacon BR, et al. Boceprevir for untreated chronic HCV genotype1 infection. N Engl J Med 2011, 364(13):1195-1206. 10.1056/NEJMoa1010494, 21449783.
33. Chesney MA, Ickovics JR, Chambers DB, et al. Self-reported adherence to antiretroviral medications among participants in HIV Clinical Trials: the AACTG adherence instruments. AIDS Care 2000, 12(3):255-266. 10.1080/09540120050042891, 10928201.
34. Handelsman L, Cochrane KJ, Aronson MJ, Ness R, Rubenstein KJ, Kanof PD. Two new rating scales for opiate withdrawal. Am J Drug Alcohol Abuse 1987, 13(3):293-308. 10.3109/00952998709001515, 3687892.
35. McLellan AT, Kushner H, Metzger D, Peters R, Smith I, Grissom G, Pettinati H, Argeriou M. The fifth edition of the addiction severity index. J Subst Abuse Treat 1992, 9:199-213. 10.1016/0740-5472(92)90062-S, 1334156.
36. Saunders JB, Aasland OG, Babor TF, et al. Development of the alcohol use disorders identification test (AUDIT): WHO collaborative project on early detection of persons with harmful alcohol consumption. II Addiction 1993, 88:791-804.
37. Edlin B. Integrated vs. Separate Care for Hepatitis C, Substance Abuse, and HIV Prevention (NIDA R01DA029512; PI: B Edlin).
38. Carver CS, Scheier MF, Wintraub JK. Assessing coping strategies: A theoretically based approach. Journal of Personality and Social Psychology 1989, 56(2):267-283.
39. Beck A, Ward C, Mendelson M. An Inventory for Measuring Depression. Archives of Psychiatry 1961, 4:561-567.
40. Dieperink E, Ho SB, Thuras P, Willenbring ML. A prospective study of neuropsychiatric symptoms associated with interferon alpha-2b and ribavirin therapy for patients with chronic hepatitis C. Psychosomatics 2003, 44:104-112. 10.1176/appi.psy.44.2.104, 12618532.
41. Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med 2001, 16(9):606-613. 10.1046/j.1525-1497.2001.016009606.x, 1495268, 11556941.
42. Derogatis LR, Spencer PM. The Brief Symptom Inventory (BSI): administration, scoring and procedure manual - 1. 1982, Baltimore, MD: John Wiley.
43. Fontana RJ, Schwartz SM, Gebremariam A, Lok AS, Moyer CA. Emotional distress during interferon-alpha-2B and ribavirin treatment of chronic hepatitis C. Psychosomatics 2002, 43(5):378-385. 10.1176/appi.psy.43.5.378, 12297606.
44. Gavazzi SM, Julian TW, McKenry PC. Utilization of the Brief Symptom inventory to discriminate between violent and nonviolent male relationship partners. Psychol Rep 1996, 79(3 Pt 1):1047-1056.
45. Russell D. The UCLA Loneliness Scale (Version 3): reliability, validity, and factor structure. Journal of Personality Assessment 1996, 66:20-40. 10.1207/s15327752jpa6601_2, 8576833.
46. Sherbourne CD, Stewart AL. The MOS Social Support Survey. Soc Sci Med 1991, 32(6):705-714. 10.1016/0277-9536(91)90150-B, 2035047.
47. Marin G, Sabogal F, VanOss Marin B, Otero-Sabogal F, Perez-Stable EJ. Development of a short acculturation scale for Hispanics. Hispanic J Behavioral Sciences 1987, 9:183-205.
48. Cortes DE, Rogler LH, Malgady RG. Biculturality among Puerto Rican adults in the United States. Am J Community Psychology 1994, 22(5):707-721.
49. Bakken S, Holzemer WL, Brown MA, Powell-Cope GM, Turner JG, Inouye J, et al. Relationships between perception of engagement with health care provider and demographic characteristics, health status, and adherence to therapeutic regimen in persons with HIV/AIDS. AIDS Patient Care STDS 2000, 14(4):189-197. 10.1089/108729100317795, 10806637.
50. Benedict RHB, Schretien D, Groninger L, Brandt J. Hopkins Verbal Learning Test - revised: normative data and analysis of inter-form and test-retest reliability. The Clinical Neuropsychologist 1998, 12(1):43-55.
51. Wilkinson GS. The Wide Range Achievement Test: Manual. 1993, Wilmington, DE: Wide Range, 3.
52. Weschler Abbreviated Scale of Intelligence. 1997, (WAIS-3®). San Antonio, TX: Harcourt Assessment, 3.